Tag:
Johnson & Johnson
Latest Headlines
Latest Headlines
Syringe cracks prompt J&J Janssen recall
A production line for J&J unit Janssen's antipsychotic drug Invega Sustenna is back in operation following an investigation into cracked syringes. A 70,000-dose recall is under way. Users are
J&J recalls long-lasting Invega on syringe cracks
Cracks in syringes prompted Johnson & Johnson to recall 70,000 doses of its long-lasting antipsychotic drug Invega Sustenna. Produced by the J&J prescription drugs unit Janssen, rather than
Crucell wins back WHO with plant power fixes
One of the dark clouds hanging over Johnson & Johnson is lifting. The World Health Organization has green-lighted Dutch vaccine-maker--and J&J quarry--Crucell to resume supplying the
J&J's Cordis lays off, merges sales staff
With demand for its Cypher heart stent diminishing, Johnson & Johnson medical device subsidiary Cordis will lay off some sales reps and merge its cardiovascular and endovascular units sales
J&J pays out $482M in patent infringement case
A Texas court has ruled that Johnson & Johnson subsidiary Cordis infringed three patents held by interventional radiologist Bruce Saffran when the company developed its bestselling line of drug
3M, beleagured J&J, announce financial results
It's earnings time, and a number of big players have announced their Q4 and yearly results, including Johnson & Johnson ( $JNJ ) and 3M ( MMM ). And, perhaps not unexpectedly, pharma/device giant
J&J CEO: More McNeil recalls possible
CEO Bill Weldon says Johnson & Johnson has reviewed operations for every McNeil product manufactured in-house, about 80 percent of the portfolio. The focus shifts now to the 20 percent
J&J recalls knock down earnings, profits
We've watched Johnson & Johnson ( $JNJ ) suffer one negative headline after another. Now, we can put a number on that suffering. J&J reported fourth quarter earnings today, posting a 12 percent
J&J shrinks bonuses for rank-and-file workers
Johnson & Johnson's reputation may be suffering from the steady drumbeat of consumer-drug recalls, but now, its employees are suffering, too. Specifically, their bonus checks are deflating. All
J&J teams up with Sanford-Burnham on Alzheimer's pact
The drug development arm of Johnson & Johnson is joining research forces with scientists at the prestigious Sanford-Burnham Institute in an effort to blaze a relatively short path to new drugs
